NANJING WELL PHARMACEUTICAL GROUP CO.,LTD. Financials Nanjing Well Pharmaceutical Group Co.,Ltd.
Equities
603351
CNE100003JD4
Oil & Gas Refining and Marketing
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.54 CNY | +0.20% |
|
-4.55% | -6.94% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 3,296 | 2,979 | 5,118 | 2,930 | 3,572 |
| Enterprise Value (EV) 1 | 2,876 | 2,823 | 5,226 | 3,256 | 3,900 |
| P/E ratio | 25.4 x | 29.6 x | 51.5 x | 30.5 x | 31.8 x |
| Yield | 1.27% | 1.32% | 0.77% | 1.29% | 1.14% |
| Capitalization / Revenue | 3.74 x | 4.05 x | 4.91 x | 2.64 x | 3.09 x |
| EV / Revenue | 3.26 x | 3.84 x | 5.01 x | 2.93 x | 3.37 x |
| EV / EBITDA | 15.6 x | 19.9 x | 32.3 x | 18.1 x | 19.5 x |
| EV / FCF | -438 x | -725 x | -24.4 x | -36.2 x | -166 x |
| FCF Yield | -0.23% | -0.14% | -4.1% | -2.77% | -0.6% |
| Price to Book | 2.66 x | 2.29 x | 3.84 x | 1.98 x | 2.25 x |
| Nbr of stocks (in thousands) | 1,30,667 | 1,30,667 | 1,30,667 | 1,35,478 | 1,35,439 |
| Reference price 2 | 25.22 | 22.80 | 39.17 | 21.63 | 26.37 |
| Announcement Date | 20/04/20 | 12/04/21 | 18/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 801.5 | 880.8 | 736.1 | 1,042 | 1,111 | 1,156 |
| EBITDA 1 | 153.6 | 184.9 | 142.2 | 161.8 | 180.2 | 199.7 |
| EBIT 1 | 125.8 | 151.1 | 108 | 122.5 | 117 | 132.2 |
| Operating Margin | 15.69% | 17.16% | 14.67% | 11.75% | 10.53% | 11.44% |
| Earnings before Tax (EBT) 1 | 131 | 154.1 | 118.3 | 118.7 | 112.9 | 121.4 |
| Net income 1 | 111.8 | 128.1 | 100.4 | 101.4 | 95.03 | 112.2 |
| Net margin | 13.95% | 14.55% | 13.65% | 9.73% | 8.55% | 9.71% |
| EPS 2 | 1.143 | 0.9929 | 0.7700 | 0.7600 | 0.7100 | 0.8300 |
| Free Cash Flow 1 | -12.89 | -6.571 | -3.896 | -214.4 | -90.04 | -23.51 |
| FCF margin | -1.61% | -0.75% | -0.53% | -20.57% | -8.1% | -2.03% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.3061 | 0.3214 | 0.3000 | 0.3000 | 0.2800 | 0.3000 |
| Announcement Date | 16/04/19 | 20/04/20 | 12/04/21 | 18/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 54.3 | - | - | 107 | 325 | 328 |
| Net Cash position 1 | - | 420 | 156 | - | - | - |
| Leverage (Debt/EBITDA) | 0.3537 x | - | - | 0.6637 x | 1.804 x | 1.643 x |
| Free Cash Flow 1 | -12.9 | -6.57 | -3.9 | -214 | -90 | -23.5 |
| ROE (net income / shareholders' equity) | 19.5% | 13.8% | 7.91% | 7.46% | 6.59% | 7.1% |
| ROA (Net income/ Total Assets) | 10.2% | 8.34% | 4.36% | 4.4% | 3.68% | 3.74% |
| Assets 1 | 1,091 | 1,537 | 2,303 | 2,303 | 2,585 | 2,999 |
| Book Value Per Share 2 | 6.270 | 9.500 | 9.950 | 10.20 | 10.90 | 11.70 |
| Cash Flow per Share 2 | 0.4100 | 1.380 | 0.5800 | 0.4900 | 0.7400 | 1.160 |
| Capex 1 | 76.9 | 121 | 282 | 236 | 234 | 73.1 |
| Capex / Sales | 9.6% | 13.69% | 38.37% | 22.61% | 21.05% | 6.32% |
| Announcement Date | 16/04/19 | 20/04/20 | 12/04/21 | 18/04/22 | 24/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.94% | 46Cr | |
| +10.94% | 23TCr | |
| +5.65% | 10TCr | |
| +27.38% | 10TCr | |
| +9.52% | 6.18TCr | |
| +17.79% | 6.16TCr | |
| +21.92% | 5.18TCr | |
| +24.95% | 3.71TCr | |
| +26.22% | 2.69TCr | |
| -12.76% | 2.09TCr |
- Stock Market
- Equities
- 603351 Stock
- Financials Nanjing Well Pharmaceutical Group Co.,Ltd.
